ID: ALA3407519

Max Phase: Preclinical

Molecular Formula: C18H19N5O6S

Molecular Weight: 433.45

Molecule Type: Small molecule

Representations

Canonical SMILES:  Nc1nc2[nH]cc(CCc3ccc(C(=O)N[C@@H](CCC(=O)O)C(=O)O)s3)c2c(=O)[nH]1

Standard InChI:  InChI=1S/C18H19N5O6S/c19-18-22-14-13(16(27)23-18)8(7-20-14)1-2-9-3-5-11(30-9)15(26)21-10(17(28)29)4-6-12(24)25/h3,5,7,10H,1-2,4,6H2,(H,21,26)(H,24,25)(H,28,29)(H4,19,20,22,23,27)/t10-/m0/s1

Standard InChI Key:  CTSPVOIVQCLQLX-JTQLQIEISA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 433.45

Molecular Weight (Monoisotopic): 433.1056

AlogP: 0.73

#Rotatable Bonds: 9

Polar Surface Area: 191.26

Molecular Species: ACID

HBA: 7

HBD: 6

#RO5 Violations: 1

HBA (Lipinski): 11

HBD (Lipinski): 7

#RO5 Violations (Lipinski): 2

CX Acidic pKa: 3.65

CX Basic pKa: 3.10

CX LogP: 0.52

CX LogD: -5.24

Aromatic Rings: 3

Heavy Atoms: 30

QED Weighted: 0.28

Np Likeness Score: -0.30

References

1. Wang Y, Mitchell-Ryan S, Raghavan S, George C, Orr S, Hou Z, Matherly LH, Gangjee A..  (2015)  Novel 5-substituted pyrrolo[2,3-d]pyrimidines as dual inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase and as potential antitumor agents.,  58  (3): [PMID:25602637] [10.1021/jm501787c]

Source

Source(1):

• Scientific Literature